HLS Therapeutics (HLS Therapeutics) Cash-to-Debt : 0.25 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HLS Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.25.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, HLS Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for HLS Therapeutics's Cash-to-Debt or its related term are showing as below:

HLTRF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 0.26 Max: No Debt
Current: 0.25

During the past 13 years, HLS Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.11. And the median was 0.26.

HLTRF's Cash-to-Debt is ranked worse than
71.88% of 1049 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs HLTRF: 0.25

HLS Therapeutics Cash-to-Debt Historical Data

The historical data trend for HLS Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

HLS Therapeutics Cash-to-Debt Chart

HLS Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.51

0.19

0.22

0.21

0.25

HLS Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.21	0.22	0.22	0.24	0.25

Competitive Comparison of HLS Therapeutics's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Cash-to-Debt falls into.

HLS Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

HLS Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	21.952	/	(5.156	+	82.465)
	=	0.25

HLS Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	21.952	/	(5.156	+	82.465)
	=	0.25

HLS Therapeutics (OTCPK:HLTRF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

HLS Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (HLS Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HLS:Canada

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA • 03-21-2013